Targeting of drugs with liposomes

  • G Gregoriadis


At least two options are open to us in pursuing optimal drug action (Gregoriadis, 1981a). In the first, creation of specialised molecules, a therapeutically profitable target-drug relationship is usually far from ideal and undesirable side effects are almost always present. In the second, drug molecules that are not necessarily target specific are transported by a carrier to the area of action and subsequently allowed to perform their task. Transport by the carrier should be effected in isolation from the biological space existing between the site of application and the site of action as this would be useful in cases where drugs are either prone to premature excretion and inactivation or detrimental to the non-target space in the host. The carrier itself should be non-toxic, biodegradable and of the appropriate shape and size so as to enable accommodation of a wide variety of therapeutic agents. It should preferably ignore or be ignored by irrelevant (normal) areas and have a pronounced affinity for, and access to the target site within which there should be a mechanism for the release of agents from the carrier. The latter, having accomplished its function, should then be disposed of.


Cholesterol Content Cutaneous Leishmaniasis Lysosomal Storage Disease Muramyl Dipeptide Liposomal Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alving, C.R., Steck, E.A., Chapman, Jr, W.L., Waits, V.B., Hendricks, L.D., Swartz, Jr., G.M.., Hanson, W.L. (1978). Therapy of leishmaniasis: superior efficacies of liposome encapsulated drugs. Proc. Nat. Acad. Sci. USA, 75, 2959–63.Google Scholar
  2. Black, C.D.V., Watson, C.J., Ward, R.J. (1977). The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans. Roy. Soc. Trop. Med. Hyg. 71, 550–52.Google Scholar
  3. Chobanian, J.V., Tall, A.R., Brecher, P.I. (1979). Interaction between unilamellar egg yolk lecithin vesicles and human high density lipoproteins. Biochemistry, 18, 180–87.Google Scholar
  4. Dapergolas, G. and Gregoriadis, G. (1976) Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats. Lancet ii, 824–27.Google Scholar
  5. Fidler, I.J. (1980). Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science, 108, 1469–71.Google Scholar
  6. Gregoriadis, G., (1981). Liposomes: a role in vaccines?. Clin Immunol Newsl. 2, 33–36.Google Scholar
  7. Gregoriadis, G., Manesis, E.K. (1980). Liposomes as immunological adjuvants for hepatitis B surface antigens. In: Liposomes and immunobiology (eds. B.H. Tom and H.R. Six). Elsevier/North Holland, New York, Amsterdam.Google Scholar
  8. Gregoriadis, G. (1981a). Targeting of drugs: implications in medicine. The Lancet, 2, 241–247.Google Scholar
  9. Gregoriadis, G., Senior, J. and Trouet, A. (eds.) (1982a). Targeting of drugs. Plenum, New York.Google Scholar
  10. Gregoriadis, G. and Senior, J. (1980). The phospholipid components of small unilamellar liposome controls the rate of clearance of entrapped solutes from the circulation. FEBS Lett 119, 43–46.Google Scholar
  11. Gregoriadis, G. (1983). Liposomes Technology. CRC Press Inc. Florida (In press). Leserman, L.D. and Barbet, J. (eds.) (1982). Méthodologie des liposomes, Inserm, Paris.Google Scholar
  12. Huang, A., Huang, L. and Kennel, S.J. (1980). Monoclonal antibody covalently coupled with fatty acid. J. Biol. Chem., 255, 8015–8018.Google Scholar
  13. Kirby, C. and Gregoriadis, G. (1981). Plasma-induced release of solutes from small unilamellar liposomes is associated with pore formation in the bilayers. Biochem. J. 199, 251–254.Google Scholar
  14. Kirby, C., Clark, J. and Gregoriadis, G. (1980a). Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 186, 591–598.Google Scholar
  15. Kirby, C., Clarke, J. and Gregoriadis, G. (1980b). Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum. FEBS Lett 111, 324–328.Google Scholar
  16. Kirby, C. and Gregoriadis, G. (1980). The effect of the cholesterol content of small unilamellar liposomes on the fate of their lipid components in vivo. Life Sci, 27, 2223–2230.Google Scholar
  17. Leserman, L.D., Barbet, J., Kourisky, F. and Weinstein, J.N. (1980). Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody of protein A. Nature, 288, 602–604.Google Scholar
  18. Mauk, M.R., Gamble, R.C. and Baldeschwieler, J.D. Targeting of lipid vesicles: specificity of carbohydrate receptor analogues for leucocytes in mice. Proc. Nat. Acad. Sci. USA 77, 4430–4434.Google Scholar
  19. McCullough, H.N. and Juliano, R.L. (1979). Organ-selective action of an antitumour drug: pharmacologic studies of liposome-encapsulated β-cytosine arabinoside administered via the respiratory system of the rat. J. Nat. Cancer. Inst., 63, 727–731.Google Scholar
  20. New, R.R.C., Chance, M.L., Thomas, S.C. and Peters, W. (1978). Antileishmanial activity of antirnonial entrapped in liposomes. Nature, 272, 55–56.Google Scholar
  21. Osborne, M.P., Richardson, V.J., Jehasingh, K. and Ryman, B.E. (1979). Radionuclide-labelled liposomes: a new lymph node imaging agent. J. Nucl. Med. Biol., 675–683.Google Scholar
  22. Poste, G., Kirsh, R., Fogler, W.E. and Fidler, I.J. (1979). Activation of tumourcidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res., 39, 881–892.Google Scholar
  23. Poste, G. (1980). The interaction of lipid vesicles (liposomes) with cultured cells and their use as carriers for drugs and macromolecules. In: Liposomes in biological systems. (eds. G. Gregoriadis and A.C. Allison) John Wiley and Sons. Chichester, New YorkGoogle Scholar
  24. Rahman, Y.E. (1980). Liposomes and chelating agents. In: Liposomes in biological systems. (eds. G. Gregoriadis, and A.C. Allison. John Wiley and Sons. Chichester, New York.Google Scholar
  25. Ryman, B.E., Jewkes, R.F. and Jegsingh, K. (1978) Potential applications of liposomes to therapy. Ann NY Acad Sci, 308, 281–307.Google Scholar
  26. Gregoriadis, G., Weereratne, H., Blair, H. and Bull, G.M. (1982b) Liposomes in Gaucher’s disease type I: use in therapy and the creation of an animal model. In: Gauchers disease. The most prevalent Jewish genetic disease (ed. R.J. Desnick) Alan L. Liss, New York.Google Scholar
  27. Gregoriadis, G. and Neerunjun, E.D., (1975). Homing of liposomes to target cells. Biochem. Biophys. Res. Comm. 65, 537–44.Google Scholar
  28. Heath, T.D., Fraley, R.T. and Papahadjopoulos, D. (1980). Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab’) to vesicle surface. Science, 210, 539–41.Google Scholar
  29. Hemker, HJ.C., Muller, A.D., Hermans, W. Th. and Swaal, R.F.A. (1980). Oral treatment of haemophilia A by gastrointestinal absorption of factor VIII entrapped in liposomes. Lancet, i, 70–71.Google Scholar
  30. Scherphof, G., Roerdink, F., Waite, M. and Parks, J. (1978). Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim. Biophys. Acta. 542, 296–307.Google Scholar
  31. Segal, A.W., Gregoriadis, G. and Black, C.D.V. (1975). Liposomes as vehicles for the local release of drugs. Clin. Sci. Mol. Med., 49, 99–106.Google Scholar
  32. Senior, J. and Gregoriadis, G. (1982). Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci. 30, 2123–2136.Google Scholar
  33. Szmuness, S., Stevens, C.E., Harley, E.J., Zang, E.A., Eleszko, W.R., Williams, D.C., Sadovsky, R., Morrison, J.M. and Kellner, A. (1980). Hepatitis B vaccine. Demonstration of efficiency in a controlled clinical trial in a high risk population in the USA. N. Engl. J. Med. 303, 833–841.Google Scholar
  34. Weinstein, J.N., Magin R.L., Yatvin, M.B. and Saharko, D.S. (1979). Liposomes and local hyperthermia; delivery of methotrexate to heated tumours. Science, 204, 188–91.Google Scholar
  35. Yatvin, M.B., Kreutz, W., Horwitz, B.A. and Shinitzky, M. (1980). pH-sensitive liposomes: Possible clinical implications. Science, 210, 1353–55.Google Scholar

Copyright information

© The Contributors 1983

Authors and Affiliations

  • G Gregoriadis
    • 1
  1. 1.Division of Clinical SciencesClinical Research CentreMiddlesexUK

Personalised recommendations